Sugi Predict

Sugi Predict / Compounds / SCHEMBL820141

SCHEMBL820141

SCHEMBL820141

COC(=O)c1ccc(C(=O)O)cc1C(=O)OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 10/20 0.55
▸ ALDH1A1 P00352 4/20 0.55
▸ HSD17B10 Q99714 3/20 0.55
▸ HPGD P15428 3/20 0.55
▸ ATM Q13315 3/20 0.55
▸ GAA P10253 3/20 0.55
▸ GLA P06280 2/20 0.55
▸ MAPT P10636 1/20 0.55
▸ CASP1 P29466 1/20 0.55
▸ CASP7 P55210 1/20 0.55
▸ CA1 P00915 4/20 0.50
▸ CA2 P00918 4/20 0.50
▸ CA12 O43570 3/20 0.50
▸ CA7 P43166 3/20 0.50
▸ CA9 Q16790 3/20 0.50
▸ CA14 Q9ULX7 3/20 0.50
▸ KDM6B O15054 1/20 0.50
▸ KDM5C P41229 1/20 0.50
▸ KDM4C Q9H3R0 1/20 0.50
▸ KDM2A Q9Y2K7 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29699657 1.00 KDM4E (0.55) KDM4EALDH1A1HSD17B10HPGDATM
SCHEMBL5834949 0.94 KDM4E (0.50) KDM4EALDH1A1HSD17B10HPGDATM
SCHEMBL293611 0.94 KDM4E (0.55) KDM4EALDH1A1HSD17B10HPGDATM
SCHEMBL293610 0.94 KDM4E (0.53) KDM4EALDH1A1HSD17B10HPGDATM
SCHEMBL17893501 0.88 KDM4E (0.47) KDM4EALDH1A1HSD17B10HPGDATM
SCHEMBL126043 0.88 KDM4E (0.69) KDM4EALDH1A1HSD17B10HPGDATM
SCHEMBL29492994 0.88 KDM4E (0.69) KDM4EALDH1A1HSD17B10HPGDATM
SCHEMBL9080431 0.86 KDM4E (0.62) KDM4EALDH1A1HSD17B10HPGDATM
SCHEMBL30967314 0.86 KDM4E (0.62) KDM4EALDH1A1HSD17B10HPGDATM
SCHEMBL3767347 0.86 KDM4E (0.62) KDM4EALDH1A1HSD17B10HPGDATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117623916-A Method for preparing trimellitate by using heavy component of meta-anhydride 南通百川新材料有限公司 2024-03-01 — — CN claimed
EP-1567470-B1 HYDROGENATION OF BENZENE POLYCARBOXYLIC ACIDS OR DERIVATIVES THEREOF EXXONMOBIL CHEM PATENTS INC (US) 2013-06-05 — — EP claimed
US-7595420-B2 Hydrogenation of benzene polycarboxylic acids or derivatives thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2009-09-29 — — US claimed
US-20060247461-A1 Hydrogenation of benzene polycarboxylic acids or derivatives thereof EXXONMOBIL CHEMICAL PATENTS INC. 2006-11-02 — — US claimed
EP-1567470-A1 HYDROGENATION OF BENZENE POLYCARBOXYLIC ACIDS OR DERIVATIVES THEREOF ExxonMobil Chemical Patents Inc. (US) 2005-08-31 — — EP claimed
WO-2004046078-A1 HYDROGENATION OF BENZENE POLYCARBOXYLIC ACIDS OR DERIVATIVES THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2004-06-03 — — WO claimed
CN-117623916-A Method for preparing trimellitate by using heavy component of meta-anhydride 南通百川新材料有限公司 2024-03-01 — — CN disclosed
CN-117623916-A Method for preparing trimellitate by using heavy component of meta-anhydride 南通百川新材料有限公司 2024-03-01 — — CN disclosed
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2023-10-19 — — US disclosed
EP-3660004-B1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS INC (US) 2023-02-22 — — EP disclosed
US-11236051-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2022-02-01 — — US disclosed
CN-113412286-A Process for preparing polydienes having reduced cold flow properties 普利司通美国轮胎运营有限责任公司 2021-09-17 — — CN disclosed
US-20210009528-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas, Inc. 2021-01-14 — — US disclosed
WO-1999048371-A1 NOVEL HIV INTEGRASE INHIBITORS AND HIV THERAPY BASED ON DRUG COMBINATIONS INCLUDING INTEGRASE INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-09-30 — — WO disclosed
EP-0560984-B1 FLEXIBLE MEMBER FOR MEDICAL USE TERUMO CORP (JP) 1999-05-26 — — EP disclosed
EP-0882703-A1 CYCLIC AMIC ACID DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 1998-12-09 — — EP disclosed
US-5480394-A POLYLACTONE, GLYCERIDE, BLOOD BAG TERUMO KABUSHIKI KAISHA (JP) 1996-01-02 — — US disclosed
US-5466858-A Ruthenium catalyst, high selectivity with a carboxylic acid UBE INDUSTRIES, LTD. (JP) 1995-11-14 — — US disclosed
EP-0560984-A1 FLEXIBLE MEMBER FOR MEDICAL USE TERUMO KABUSHIKI KAISHA (JP) 1993-09-22 — — EP disclosed
US-4145366-A ACID CATALYST TEIJIN LIMITED (JP) 1979-03-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN KDM4E 706/4885ALDH1A1 798/4885HSD17B10 332/4885
US-20210009528-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN KDM4E 706/4885ALDH1A1 798/4885HSD17B10 332/4885
US-11236051-B2 Compounds and methods for the targeted degradation of androgen receptor AR, ADRM1, CRBN KDM4E 706/4885ALDH1A1 798/4885HSD17B10 332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.